Counterpoint:次季拉美智能手機出貨量升41.8% 小米(01810.HK)市佔第三出貨量倍增
據調查機構Counterpoint發表的報告指,今年第二季拉丁美洲智能手機出貨量按年升41.8%,不過按季比較則跌6.5%,期內拉丁美洲受疫情困擾,僅數個國家有過半人口接種疫苗,因此大部分地區均受封城、經濟減慢等影響,拖累平均銷售單價表現。
按品牌劃分,期內三星市佔率第一,達42.5%,Motorola則以22%市佔率排第二,小米(01810.HK)增長為當地最強,銷量按年升逾兩倍,主要受惠華為出貨呈跌勢,帶動公司成為當地第三大品牌,不過料來自其他中國品牌的競爭增加,或會令小米增長放慢。(el/s) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.